Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of “Buy” by Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been assigned a consensus rating of “Buy” from the eight brokerages that are covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $71.40.

Several research firms recently weighed in on ARCT. Leerink Partnrs raised Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. HC Wainwright boosted their price objective on shares of Arcturus Therapeutics from $60.00 to $63.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. William Blair restated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Thursday, May 23rd. Leerink Partners assumed coverage on shares of Arcturus Therapeutics in a research report on Monday, August 12th. They issued an “outperform” rating and a $70.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th.

Arcturus Therapeutics Stock Up 4.2 %

NASDAQ:ARCT opened at $20.75 on Monday. Arcturus Therapeutics has a 52 week low of $17.52 and a 52 week high of $45.00. The company has a fifty day simple moving average of $21.33 and a two-hundred day simple moving average of $27.68. The company has a market cap of $558.80 million, a price-to-earnings ratio of -5.31 and a beta of 2.60.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The firm had revenue of $49.86 million for the quarter, compared to analyst estimates of $21.00 million. During the same period last year, the firm posted ($1.98) EPS. On average, analysts expect that Arcturus Therapeutics will post -2.6 EPS for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

Several large investors have recently added to or reduced their stakes in ARCT. Millennium Management LLC lifted its holdings in Arcturus Therapeutics by 250.1% during the 2nd quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock worth $13,515,000 after buying an additional 396,505 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Arcturus Therapeutics by 22.4% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock worth $38,061,000 after buying an additional 286,546 shares during the period. ARK Investment Management LLC lifted its holdings in shares of Arcturus Therapeutics by 16.3% in the second quarter. ARK Investment Management LLC now owns 1,964,964 shares of the biotechnology company’s stock valued at $47,847,000 after purchasing an additional 275,315 shares in the last quarter. Great Lakes Advisors LLC acquired a new position in shares of Arcturus Therapeutics during the fourth quarter worth about $6,531,000. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Arcturus Therapeutics by 11.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,088,930 shares of the biotechnology company’s stock worth $34,336,000 after buying an additional 115,087 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.